Short answer
Korro Bio, Inc. (KRRO) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $1M with net income of −$18M.
Q3 2025 key financials · XBRL
- Revenue
- $1M
- −25.3% QoQ
- Net income
- −$18M
- +14.0% YoY · +29.9% QoQ
- Operating margin
- -1764.9%
- EPS (diluted)
- −$1.92
- +14.3% YoY · +30.2% QoQ
Source: XBRL data from the Korro Bio, Inc. (KRRO) Q3 2025 10-Q on SEC EDGAR. USD.
Korro Bio, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- AATD program pivot: KRRO-110 failed to reach projected protein levels, prompting a shift from LNP to GalNAc delivery
- Cash runway $102.5 million excluding restricted cash, expected to fund operations into the second half of 2027
- FDA and other regulators may require additional studies, delay trials, or impose stricter approval conditions
- April 2025 tariffs threaten clinical-site operations and patient enrollment through higher supply-chain costs
- KRRO-110 remains the only clinical candidate, while all other programs are research or preclinical-stage pipeline assets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Korro Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.